CHIRAL BISOXAZOLIDINES: A NEW CLASS OF LIGANDS FOR ASYMMETRIC CATALYSIS

许多具有生物活性的化合物都是手性的，目前超过50%的畅销药物是以单对映体的形式上市的。对对映纯化合物不断增长的高需求要求不对称合成技术不断取得进展。特别是，开发新的催化剂仍然是至关重要的。具有刚性c2对称支架的手性双恶唑烷类化合物在不对称催化方面具有很好的应用前景。这类新的N， o给体将应用于具有挑战性的对映选择性碳-碳键形成反应。有了这个奖项，有机合成：方法论和有机金属项目支持乔治城大学化学系的克里斯蒂安·沃尔夫教授的研究。沃尔夫教授的研究旨在开发用于不对称催化的新型手性双恶唑烷配体。研究双恶唑烷催化反应的机理，并努力调整这类配体的催化效率和不对称诱导。新型不对称催化剂的成功开发有望为复杂手性靶分子的合成提供新的工具。这将对制药、食品和农业产生影响。

Many biologically active compounds are chiral, and more than 50% of today's top-selling drugs are marketed as single enantiomers. The high and ever-increasing demand for enantiopure compounds requires constant progress in asymmetric synthesis. In particular, the development of new catalysts continues to be crucial. Chiral bisoxazolidines with a rigid C2-symmetric scaffold have very promising applications in asymmetric catalysis. This new class of N,O-donor ligands will be applied in challenging enantioselective carbon-carbon bond formation reactions. With this award, the Organic Synthesis: Methodology and Organometallic Program is supporting the research of Professor Christian Wolf of the Department of Chemistry at Georgetown University. Professor Wolf's research is aimed at the development of new chiral bisoxazolidine ligands for asymmetric catalysis. Studies to elucidate the mechanism of bisoxazolidine-catalyzed reactions and efforts to fine-tune the catalytic efficiency and asymmetric induction of this class of ligands will be undertaken. The successful development of new asymmetric catalysts is expected to provide new tools for the synthesis of complex chiral target molecules. This will have an impact on the pharmaceutical, food, and agricultural industries.